Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients

Background A variety of autologous tumor/dendritic-cell (DC) vaccines have been pursued. Our prior autologous tumor/ DC fusion (dendritoma) vaccine demonstrated clinical benefit in metastatic melanoma; however, dendritoma production is difficult and not scalable for commercialization. We developed an alternative, novel approach to efficiently deliver the autologous tumor antigenic repertoire to the cytoplasm of phagocytic-DC using yeast cell wall particles (YCWP). We describe the in vitro and animal data supporting clinical development of our tumor lysate, particle-loaded, DC(TLPLDC) vaccine.